{"id":446122,"title":"Diamorphine being added to list of opioids (Part B): Notice of amendment - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-01-03","captureTimestamp":"2026-01-03T11:10:43.895000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/reports-publications/medeffect-canada/submission-targeted-rm-plans-commitments-prescription-opioid-containing-products-guidance-industry/diamorphine-added-list-opioids-part-b.html?wbdisable=false","snippet":"Diamorphine being added to list of opioids (Part B): Notice of amendment Date: January 14, 2022 This notice of amendment is to notify stakeholders that Health Canada has amended Part B of the List of Opioids . Specifically, we have added the active ingredient \"diamorphine\" to…","rawSnapshotUrl":"/api/snapshots/raw/446122","browseUrl":"https://replay.healtharchive.ca/job-6/20260103111043/https://www.canada.ca/en/health-canada/services/drugs-health-products/reports-publications/medeffect-canada/submission-targeted-rm-plans-commitments-prescription-opioid-containing-products-guidance-industry/diamorphine-added-list-opioids-part-b.html?wbdisable=false#ha_snapshot=446122","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}